Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBITDA (2016 - 2025)

Sunshine Biopharma's EBITDA history spans 13 years, with the latest figure at -$1.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 40.27% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$5.2 million, up 21.76%, while the annual FY2025 figure was -$5.2 million, 21.76% up from the prior year.
  • EBITDA reached -$1.9 million in Q4 2025 per SBFM's latest filing, down from -$1.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $661452.0 in Q4 2021 to a low of -$23.3 million in Q4 2022.
  • Average EBITDA over 5 years is -$2.7 million, with a median of -$1.4 million recorded in 2024.
  • The largest YoY upside for EBITDA was 161.11% in 2021 against a maximum downside of 6371.96% in 2021.
  • A 5-year view of EBITDA shows it stood at $661452.0 in 2021, then crashed by 3618.1% to -$23.3 million in 2022, then skyrocketed by 96.74% to -$758468.0 in 2023, then tumbled by 316.2% to -$3.2 million in 2024, then surged by 40.27% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBITDA are -$1.9 million (Q4 2025), -$1.5 million (Q3 2025), and -$686277.0 (Q2 2025).